Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Phase III Trial Show That the Combo of Ipilimumab and Nivolumab Increases Overall Survival in People with Kidney Cancer

By Memorial Sloan Kettering Cancer Center | March 22, 2018

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) significantly increased overall survival versus treatment with sunitinib (Sutent) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) that were reported today in the New England Journal of Medicine.

The international study, led by MSK medical oncologist and world-renowned kidney cancer expert Robert Motzer, MD, compared the combination of the two immunotherapies against sunitinib alone in people with advanced renal cell carcinoma (RCC) who had not yet received treatment. Researchers found that the combination of the immunotherapies ipilimumab and nivolumab extended overall survival, and objective response rates were significantly higher with the combination than with sunitinib alone.

“We have seen a significant improvement in overall survival,” said Dr. Motzer, lead author and principal investigator of the study. “This immunotherapy combination offers a completely different mechanism of action, and it introduces a new type of therapy in this setting. One earlier trial gave us a hint of potential, but this is the first time we have been able to demonstrate a survival benefit in a first-line therapy for renal cell carcinoma.”

In the randomized phase III trial, a total of 1,096 people who’d had no prior treatment were randomly assigned to treatment at 175 sites in 28 countries. There were 550 people treated with the nivolumab plus ipilimumab combination and 546 treated with sunitinib, the current standard of care. Researchers found a significant difference in overall survival favoring the ipilimumab and nivolumab combination, with an 18-month overall survival rate of 78 percent versus 68 percent with sunitinib alone.

This study was also designed for a formal statistical comparison between the sunitinib group and the combination group in producing objective responses (meaning substantial tumor shrinkage). Those receiving the combination also had a higher objective response. In addition, 9 percent of people in the combination trial had a complete response (with no evidence of the tumor remaining) versus 1 percent of those who received sunitinib alone.

Ipilimumab and nivolumab are part of a class of drugs called immune checkpoint inhibitors, which unleash the immune system to attack cancer. The immune system has several checkpoints in place to avoid an overreaction. Ipilimumab works by blocking the CTLA-4 checkpoint, a molecular brake that stops T cells from becoming fully and persistently activated. Similarly, nivolumab prevents the molecule PD-L1, expressed by tumors, from binding to T cells and deactivating them.

Because immunotherapy drugs work differently than targeted therapies, side effects can be significant.

Implications for People with RCC

Kidney cancer is notoriously difficult to treat. RCC, the most common form of the disease, is often diagnosed when it has already spread to other organs. Until recently, people with RCC had few therapeutic options. For years, oncologists have had very limited choices for how to treat people with metastatic RCC. The targeted therapy sunitinib was approved in 2006, based on studies led by Dr. Motzer at MSK. Since then, it has remained the standard of care as initial treatment for this disease.

More than 330,000 people are diagnosed with RCC every year, and the disease causes more than 140,000 deaths worldwide annually. It’s also particularly aggressive: At the time of diagnosis approximately 30 percent of people have metastatic disease, which means the cancer has already spread to other organs, and about one-third of people whose disease is confined to the kidney will relapse.

“This trial has produced practice-changing results in kidney cancer and represents another important step in the clinical trials program at MSK. We believe the results of this trial will now make this combination the standard of care in advanced metastatic kidney cancer,” said Dr. Motzer.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE